Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function
- 1 December 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 9 (6) , 575-586
- https://doi.org/10.1097/00041433-199812000-00010
Abstract
Epidemiological observations, clinical studies, and basic laboratory research suggest that oestrogen replacement therapy is associated with beneficial cardiovascular effects in postmenopausal women. Oestrogen has a multitude of biological effects that may account for this apparent benefit (which remain to be proven in randomized clinical trials), including favourable effects on the lipid profile, a direct effect on the vascular endothelium with increased nitric oxide bioactivity, and improved fibrinolysis. However, long-term oestrogen therapy increases the risk of breast and endometrial cancers. Raloxifene, a benzothiophene derivative that binds to the oestrogen receptor, is a selective oestrogen receptor modulator, producing oestrogen-agonistic effects in some tissues (liver, bone), and oestrogen-antagonistic effects in others (breast, uterus), and may prove to be an option for women with atherosclerosis and its associated risk factors who might benefit from oestrogen therapy. This review updates the current knowledge of the biological effects of oestrogen and selective oestrogen receptor modulators of potential cardiovascular importance in postmenopausal women.Keywords
This publication has 91 references indexed in Scilit:
- Effect of Postmenopausal Hormone Therapy on Lipoprotein(a) ConcentrationCirculation, 1998
- A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal womenArchives of internal medicine (1960), 1997
- The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 1995
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI TrialJAMA, 1995
- Hormonal Treatment of Postmenopausal WomenNew England Journal of Medicine, 1994
- Guidelines for Counseling Postmenopausal Women about Preventive Hormone TherapyAnnals of Internal Medicine, 1992
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.Circulation, 1987
- Menopause and the Risk of Coronary Heart Disease in WomenNew England Journal of Medicine, 1987